Skip to main content
Clinical Trials/NCT02068755
NCT02068755
Completed
Not Applicable

The Use of Blood Products in Patients Undergoing Cardiac Surgery

University of Turku0 sites31,000 target enrollmentJanuary 2002

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Anemia
Sponsor
University of Turku
Enrollment
31000
Primary Endpoint
Red blood cell infusions
Status
Completed
Last Updated
12 years ago

Overview

Brief Summary

Blood transfusion is a common procedure essential for the treatment of patients undergoing cardiac surgery. Inappropriate transfusions, however, not only incur needless healthcare costs, but increase unnecessary risks due to transfusion reactions and infectious and immunomodulative causes. Safe and appropriate patient care requires evaluated blood component prescription practices.

Practically all patients undergoing cardiac surgery in Finland have a blood product booking from the Finnish Red Cross Blood Service. This registry contains large volumes of transfusion-related information on all Finnish patients undergoing cardiac surgery in Finnish centers. Participating hospitals were scattered to all geographical areas in Finland and concentrated to the most populated regions.

Data on the blood product use, laboratory findings one month pre-operatively and 12 months post-operatively were available.

Finnish hospitals have been required to provide information on hospital visits for the Finnish National Research and Development Centre for Welfare and Health for healthcare planning purposes. We used in part the original data sent by hospitals to the Finnish Hospital Discharge Register (FHDR).

Detailed Description

Registry includes * \>21 000 patients who underwent coronary bypass, * \>4500 patients with aortic valve replacement, * \>4000 mitral valve operation.

Registry
clinicaltrials.gov
Start Date
January 2002
End Date
December 2012
Last Updated
12 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Dr. Pirjo Mustonen, MD, PhD

Professor

University of Turku

Eligibility Criteria

Inclusion Criteria

  • Cardiac surgery performed in Finnish University and Central hospitals
  • Blood product booking for surgery

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Red blood cell infusions

Time Frame: 12 months

Platelet infusion

Time Frame: 12 months

Fresh frozen plasma

Time Frame: 12 months

Octaplas

Time Frame: 12 months

Secondary Outcomes

  • TIA/stroke/arterial embolism(12)
  • re-operation due to bleeding(12 months)
  • myocardial infarction(12 months)
  • All cause mortality(12 months)

Similar Trials